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ABSTRACT
Background: Suitable biomarkers that have prognostic values are one of the key points of interest in
ischaemic stroke. Increased sympathetic nervous system activity in ischaemic stroke causes multiple
local and systemic effects that can be detrimental to the outcome. The mechanism of action is
increased secretion and activity of catecholamines, whose end metabolic products are vanillylmandelic
acid and homovanilic acid. Aim of our study was to determine whether these compounds can be used
as potential prognostic biomarkers in ischaemic stroke, as a unique insight into the activity of the sym-
pathetic nervous system.
Methods: Urine samples of 96 patients with ischaemic stroke and transitory ischaemic attacks were
analysed. Values of vanillylmandelic and homovanillic acids in urine were tested using liquid chroma-
tography on the first and third day post-stroke. Severity of stroke was determined using the NIHSS
scale, while functional outcome was determined using the Modified Rankin Scale.
Results: Values of vanillylmandelic and homovanillic acids positively correlated with functional out-
come of ischaemic stroke. Favorable outcomes correlated with decreased values, on contrary to
increased values, which were associated with unfavourable outcomes.
Conclusion: Determining the values of these compounds in the urine is an easily available prognostic
tool for the ischaemic stroke outcome, while also influencing potential therapeutic changes.
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Ischaemic stroke (IS), a leading cause of death and disability
in the world (Warlow 1998), is caused by disrupted blood
flow to the brain. One of the key points of interest in
research today is finding suitable biomarkers that have a
bearing on the functional outcome of the disease (Song
et al. 2012, Wakisaka et al. 2014). The complex interplay
between the central nervous system (CNS), autonomic ner-
vous system (ANS) and the immune system could be the
source of such biomarkers, as this interplay has a significant
impact on the neurological status and outcome of IS
(Gelderblom et al. 2009). Brain ischaemia leads to a disrup-
tion in the homeostasis, causing neuronal cell death and the
activation of the innate immune system. Acute inflammation
can be considered as a double-edged sword, with its benefit
being a debated topic. It is likely that the acute inflammation
is needed during the early post-ischaemia period for the
clearance of cellular debris, however it also seems that pro-
longed inflammation is neurotoxic and does not propagate
cellular repair (Doyle and Buckwalter 2012). Two different
effects of the sympathetic nervous system (SNS) activity
occur in the post-stroke period: it drives both the local acute
inflammation and the Central nervous system injury-induced
immune deficiency syndrome (CIDS) causing (or leading to)
symptoms of secondary systemic immunodepression (Dirnagl
et al. 2007). Ischaemic stroke causes an increase of catechol-
amines (CA), which activate the beta-adrenergic receptors
(b-ARs) of microglia cells and thus stimulating a cytokine pro-
duction as well as promoting a proinflammatory reaction
(Johnson et al. 2013). Cytokines produced by innate immune
cells like interleukin (IL)-1b (Besedovsky et al. 1986) or
tumour necrosis factor alpha (TNF-a) (Zielinski et al. 2013) are
necessary for the communication between the immune
and central nervous systems. TNF-a values are lowered after
central inhibition of the SNS, which indicates that the
communication between the systems goes both ways
(P€oyh€onen-Alho et al. 2008).
Sympathetic and parasympathetic nerve endings directly
innervate primary and secondary lymph organs and are in
close contact with the cells of the immune system. Leukocyte
surface receptors for neurotransmitters (catecholamines,
dopamine, acetylcholine and opiates), hormones (growth
hormone, corticosteroids and prolactin) and neuropeptides
(substance P and arginine vasopressin) have
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immunoregulatory function, both in-vivo and in-vitro. The
cytokines released from activated immune cells act on the
hypothalamus–pituitary–adrenal (HPA) axis and affect the
neuroendocrine regulation centres in the hypothalamus,
enhancing the effects of HPA and the hypothalamic–sympa-
tho–adrenomedullary axis (Chrousos 1995).
There is a systemic increase in epinephrine (EPI), norepin-
ephrine (NE) and dopamine present in ischaemic stroke and
other situations with major sympathetic activity such as
major surgery. However, there are notable differences of
dopamine levels in ischaemic stroke compared to other
states due to direct stimulation of neurons and the paraven-
tricular nucleus of the hypothalamus (Beley et al. 1991, Kao
et al. 1994, Sarkar et al. 2017).
All of the released catecholamines have to be metabolised
into inactive compounds, which represent an opportunity to
identify them as possible biomarkers. The final metabolic
products of EPI and NE is vanillylmandelic acid (VMA), after
conversion via intermediates, metanephrine/normetanephrine
and 3,4-Dihydroxyphenilglycol (DHPG) and 3-methoxy-4-
hydroxy-phenylglycol (MHPG). On the other hand, homovanil-
lic acid is the final metabolic product of dopamine, via inter-
mediate 3,4-Dihydroxyphenylacetic acid (DOPAC). VMA values
provide insight into the overall activity of the sympathetic
nervous system, while HVA provides insight into the central
dopaminergic activity and could be a differentiating factor of
sympathetic activation in ischaemic stroke compared to other
major sympathetic activation, such as major surgery (Scatton
et al. 1983). VMA and HVA are usually present in the urine in
small amounts, however they increase during and immedi-
ately after exposure of the body to stressors (Csaba 2014).
In physiological conditions, the increased synthesis of CA
results in the synergy between Adrenocorticotropic hormone
(ACTH) excreted by the pituitary gland and cortisol excreted
by the adrenal glands, which is present in chronic stress
response, as a result of increased sympathetic reaction to the
hormone (Bralley and Lord 2001). Cortisol values can impact
the values of VMA and HVA indirectly, through the negative
feedback loop in the HPA axis. Increased cortisol values can
inhibit further ACTH release that occurs in stress. As ACTH
increases production of both catecholamines and cortisol; the
overall effect of increased cortisol values could be a reduc-
tion in catecholamine values (Stephens and Wand 2012).
Similar results were found in a recent study, where elevated
corticosteroid values had a negative feedback on the sympa-
thetic axis (Mracsko et al. 2014).
Elevated levels of these metabolites are found in urine of
patients suffering from certain diseases; for example neuro-
blastomas, pheochromocytomas and other neuroendocrine
tumours that can produce large amounts of CA, resulting in
a significant increase in levels of the hormones and their
metabolites (Akimaru et al. 1994; Pacak 2011, Barco et al.
2014, van Berkel et al. 2014). Thus, finding these metabolites
is an important diagnostic indicator of some other diseases,
e.g. in children with undifferentiated tumours.
Creatinine, VMA and HVA concentration measurements
are carried out on random samples of urine and results of
these tests often list VMA, HVA and creatinine ratios.
Creatinine is excreted mainly by glomerular filtration which
makes it an important endogenous indicator of kidney func-
tion. Creatinine in urine is also determined, especially in
randomised urine testing. As creatinine is excreted in urine in
constant values, it is used for normalising values of VMA and
HVA excretion due to uncontrolled influences on their secre-
tion. (Li et al. 2002).
A number of drugs ( Shekim et al. 1982, Vaccarezza and
Ruiz 1974) and foods increase values of urinary catechol-
amines and may affect VMA testing (Numata et al. 1997,
Weldin et al. 2003), along with other factors such as acute
stress and strenuous exercise (Filaire et al. 2002).
The aim of our study was to determine the values of VMA
and HVA in random urine samples of ischaemic stroke
patients, using them as possible indicators of the severity of
stroke and to check whether changes in the ANS activity is
related to the outcome of ischaemic injury.
Clinical significance
 Vanillylmandelic and homovanilic acids are sympathetic
system activity biomarkers easily available in the urine.
 Values of VMA and HVA positively correlated with ische-
mic stroke functional outcome.
 Higher TNF-a values in severe stroke indicate higher sym-
pathetic system activity.
 VMA and HVA values provide unique insight into the
course of the disease, which could lead to novel therapies
and new windows to apply them.
Methods
Patients
Patient data and their urine samples were cared for in
accordance with the published International Health
Guidelines (Helsinki declaration, 2008). The study protocol
was approved by the local ethics committee in accordance
with World Medical Association outlines in the declaration of
Helsinki. All patients included in the study signed informed
consents (Figure 1).
In this study we examined patients suffering from ischae-
mic brain infarction.The patients were divided into three
groups according to severity of stroke: patients with acute
ischaemic brain infarction with values measured according to
NIHSS (Kelly-Hayes et al. 1998) at 12 and lower, (NIHSS 12)
patients suffering from acute ischaemic brain infarction with
NIHSS values above 12 (NIHSS >12) and patients suffering
from transient ischaemic attack (TIA), who were treated at
clinical hospital centre (CHC) Rijeka's department for neur-
ology in the period between 2012 and 2015.
Ninety-six patients were involved in the study (46 men
and 50 women, age group 65–85 years old, mean age 74.75
years and the mean± [SD]: 74.75 ± 04.06), suffering from
ischaemic stroke and TIA of middle cerebral artery (MCA)
within the first 24 hours. Studies have shown no significant
differences between the genders in VMA and HVA values.




























creatinine, which has been suggested as a cut-off point in
elderly patients by previous studies (Tohmola et al. 2015).
Diagnosis of ischaemic stroke was based on medical
history, clinical picture, neurological examination and CT
findings which confirmed the hypodensity in the MCA brain
territory. Patients were not asked to fast before sample acqui-
sition, but were informed toavoid nutrients that can affect
the VMA and HVA values in the urine. Furthermore, the
patients did not receive any serum IV replacements.
Exclusion criteria were: haemorrhagic stroke, clinical and
laboratory signs of infection at admission, oncology patients,
patients suffering from kidney and liver disease, patients suf-
fering from alcoholism and treatment with corticosteroids,
antidepressants, dopamine stimulators, clonidine and immu-
nosuppressants. The study did not include patients who
require admission to the intensive care unit and mechanical
ventilation, patients who received corticosteroids in the treat-
ment, as well as medications and nutrients which are con-
firmed to interfere with values of VMA and HVA in urine
(Numata et al. 1997, Vaccarezza and Ruiz 1974).
Neurological function was monitored, as previously stated,
in accordance with the NIHSS scale, on the first and third day
in all subjects, while degree of disability and disease out-
come were estimated in accordance with the mRS scale
(Modified Rankin Scale) (Rankin 1957, Banks and Marotta
2007) 90 days after the IS.
Sample collection procedure
30mL urine samples were taken to determine the concentra-
tion of creatinine (Cobas C501; Roche Diagnostic, Mannheim,
Germany), HVA and VMA, on the first and third day after
stroke or TIA, between 8 and 9 a.m., in the Cerebrovascular
Unit, Department of Neurology at the Clinical Hospital Centre
Rijeka (CHC Rijeka), Croatia. Concentrations of VMA and HVA
in urine were tested using high performance liquid chroma-
tography (HPLC) with electrochemical detector
(Chromsystem, Germany) at the Department of Clinical
Laboratory Diagnostics at Clinical Hospital Centre Osijek (CHC
Osijek), Croatia. A commercial kit detecting VMA, HVA and 5-
HIAA (Chromsystem, Germany) in the urine was used. Urine
sample preparation (solid-liquid extraction) was required
prior to chromatography, which included the commercial col-
umn, flow rate of 1.0ml/min, column temperature of 25 C
and the injection volume of 10 lL. The intra-assay and inter-
assay coefficients of variations were <4 and 5%. The results
were expressed as HVA and VMA /creatinine ratio (in text
referred to as values) (Link et al. 1985).
TNF-a was measured from the serum of patients using the
enzyme-linked immunosorbent assay as per the man-
ufacturer’s instructions (ELISA kit, Quantikine, R&D Systems,
Europe, UK).
Statistical analysis
For statistical analysis, we used Statistica 12 software package
(StatSoft Inc., Tulsa OK). Since the data are not distributed
normally, we used non-parametric tests. Values in the three
groups (NIHSS >12, NIHSS 12 and TIA) on the first and
third day were compared using the repeated measures ana-
lysis of variance (two-way RM-ANOVA). Post hoc test was
conducted using Fisher's least significant difference (LSD)
technique.
Figure 1. Consort flow diagram of the study.



























Connection with the degree of disability, which is a
categorical variable (1–6), is shown using Spearman's rank
correlation coefficient. Using the chi-square test, we com-
pared the differences between various categories of dis-
ability in relation to increase or decrease of HVA and
VMA ratios.
Statistical significance level was set to p 0.05, i.e. with
95% confidence limit. TNF-a values were measured using the
repeated measures analysis of variance (RM-ANOVA).
Results
Vanillylmandelic and homovanillic acid values in
comparison with stroke severity
Values of VMA and HVA were determined by comparing the
values obtained on the first and third day for all 96 patients.
Results showed no significant differences in values of VMA
(p¼ 0.389) and HVA (p¼ 0.240) in urine between the first
and third day when comparing all patients together.
However, there is a significant difference (p¼ 0.00082) in
VMA values among the three groups (milder form of IS
[NIHSS 12], severe IS [NIHSS >12] and TIA) on the first and
third day post-stroke period. Tests revealed a significant
increase in VMA values on the third day in severe IS group
(p¼ 0.003), as well as significantly reduced VMA values in
mild IS group (p¼ 0.019) compared to the first day after
stroke. As for patients suffering from TIA, no significant dif-
ferences in VMA values were noted between the first and
third day (p¼ 0.564) (Figure 2(A)). Comparison of HVA values
from the first and third day between the three groups of
patients (NIHSS >12, NIHSS 12 and TIA) revealed significant
differences between the groups (p< 0.001). HVA values in
patients suffering from severe IS significantly increased on
the third day compared to the first (p¼ 0.004), while patients
suffering from mild IS had a significant decrease in values in
the same time period (p< 0.001). Patients suffering from TIA
showed no significant difference in HVA levels (p¼ 0.458)
(Figure 2(B)).
Furthermore, when correlating NIHSS scores and VMA
(p< 0.001) and HVA (p¼ 0.006) values there is a statistically
significant correlation on the third day post stroke, while
there is no correlation between them on the first day (VMA,
p¼ 0.228; HVA, p¼ 0.805) (Table 1).
Vanillylmandelic and homovanillic acid values as stroke
outcome parameters
Nonparametric correlation was used for comparing VMA and
HVA values from the first and third day with degree of dis-
ability expressed by the mRS. The Spearman's rank
Figure 2. Vanillylmandelic acid (VMA) and homovanillic acid (HVA) values among the three groups on the first and third day post-stroke. VMA (A) and HVA (B)
values in patients with severe IS (NIHSS >12) increased on the third day, while values in patients suffering from mild IS (NIHSS 12) decreased on the third day
compared to the first day. The values were unchanged in patients with TIA. (p< 0.05).
Table 1. Correlation between vanillylmandelic acid (VMA) and homovanillic
acid (HVA) valuesand disease severity according to the NIH stroke scale
(NIHSS). There is a positive correlation between VMA/HVA values and NIHSS
score on the third day, while the correlation on the first day post-stroke is not
statistically significant.
Values Spearman's rho p value
NIHSS and VMA day 1 (lmol/mmol creatinine) 0.354 0.004
NIHSS and VMA day 3 (lmol/mmol creatinine) 0.267 0.034
NIHSS and HVA day 1 (lmol/mmol creatinine) 0.0298 0.017
NIHSS and HVA day 3 (lmol/mmol creatinine) 0.062 0.624
Table 2. Correlation between vanillylmandelic acid (VMA) and homovanillic
acid (HVA values) and degree of disability estimated to modified Rankin scale
(mRS). Spearman's rank correlation coefficients and their levels of statistical
significance. The correlation includes both the patients who had severe and
minor IS, after 90 days (n¼ 66).
Values Spearman's rho p value
MRS and VMA day 1 (lmol/mmol creatinine) 0.354 0.004
MRS and VMA day 3 (lmol/mmol creatinine) 0.267 0.034
MRS and HVA day 1 (lmol/mmol creatinine) 0.0298 0.017




























correlation coefficients and their levels of statistical signifi-
cance is shown in Table 2. The correlation includes patients
who had severe and minor IS, after 90 days (n ¼ 66).
Comparing VMA and HVA values from the first day with
the values of mRS for 90 days after IS, on a scatter plot
shows that patients whose VMA and HVA values decreased
had higher mRS, due to the higher initial values in patients
with less severe IS.
However, when comparing VMA and HVA levels from
the third day, the correlation becomes positive as it links
higher VMA and HVA values with more severe disability
(Figure 3).
Figure 3. Correlation between vanillymandelic acid (VMA) and homovanillic acid (HVA) values and the degree of disability in mRS. VMA (A,B) and HVA (C,D) values
from the patients on the first day post stroke reveal a negative correlation to outcome (modified Rankin scale – mRS). However, on the third day the correlation
becomes positive, as it links the acid values to higher mRS score.
Figure 4. TNF-a values in patients with severe, mild is and transitory ischaemic attack (TIA). TNF-a values in the severe ischaemic stroke group constantly increases
through all three time periods (1st, 3rd and 7th day post-stroke). Interestingly, TNF-a values in the mild ischaemic group significantly increase on the 3rd day post-
stroke, but decrease slightly on the 7th day post-stroke. Testing in patients with TIA didn’t show any increase or decrease of TNF-a values, which remained constant
through all time periods.



























Using the chi-squared test, we compared results of
patients whose HVA and VMA levels decreased or increased
on the third day with degree of disability expressed in mRS.
HVA (v2¼ 38.5, p 0.001) and VMA (v2¼ 35.7, p 0.001) lev-
els decreased more in patients whose mRS score was lower
(less severe disability), while levels increased in patients
whose mRS was higher (severe disability).
TNF-a as an indicator of inflammation severity
Measuring TNF-a values was performed in three time peri-
ods: first, third and seventh day’s post-stroke. In patients
with severe IS (NIHSS >12) TNF-a values significantly
increased on both third and seventh day post-stroke com-
pared to the first. While the TNF-a values of patients with
mild IS (NIHSS 12) significantly increased on the third
day compared to the first, while on the seventh day post-
stroke the values decreased compared to the third day.
Testing in patients with TIA didn’t show any increase or
decrease of TNF-a values, which remained constant
through all time periods (Figure 4).
Discussion
There is a growing body of knowledge regarding SNS activa-
tion in IS. Several papers already point out the increased cat-
echolamine levels in patients after IS and even connect the
increased levels to negative outcomes (Chamorro et al. 2007,
Akıl et al. 2015). Minimum information is known about the
full effects of SNS activation in both the brain and the whole
system. It is clear that SNS activity after stroke is increased,
while the parasympathetic nervous system (PNS) activity is
decreased, which leads to a proinflammatory state in the
early post-stroke period, with peripheral immunodepression
after the splenic reserves are depleted (Dirnagl et al. 2007).
Our results indicate that VMA and HVA values have the
same tendency to change in both groups with IS and remain
unchanged in patients with TIA. In the first group with more
severe IS (NIHSS >12), we found that the values of VMA and
HVA increase significantly from the first to the third day
post-stroke. These changes point out to the activation of the
SNS and increased release of catecholamines in the early
post-stroke period. Interestingly, the group with less severe
IS (NIHSS 12) had higher initial values of VMA and HVA in
the urine, with them decreasing significantly on the third
post-stroke day compared to the first. It appears that less
severe strokes did not activate the SNS in the same strength
as the more severe strokes, while the decrease in levels point
out to the quick damage repair and subsequent SNS deacti-
vation. The increased initial values in these patients can be
explained by a large number of substances and foods that
affect catecholamine levels along with individual variations
(Numata et al. 1997, Shekim et al. 1982, Vaccarezza and Ruiz
1974, Weldin et al. 2003). Additionally, there is a positive
correlation between the NIHSS scores and the metabolites
values in the urine only on the third day, which further indi-
cates the possible link between SNS activation and stroke
severity.
Furthermore, we found that the increase or decrease of
VMA and HVA values between the first and third day had a
positive correlation on the outcome of patients. This data
indicates that patients with unfavourable outcomes had an
increase in acid values, while patients with better outcome
had a decrease in acid values on the third day post-stroke in
both groups. The worse outcome can be related to the vari-
ous effects that increased SNS activity has an effect on the
immune, cardiovascular and metabolic systems.
The innate immune system is responsible for the initial
response to the ischaemia, with increased activation of
microglial cells and recruitment of peripheral NK cells and
monocytes due to the blood-brain barrier breakdown
(Chamorro et al. 2012). This is also evident in the increase of
proinflammatory cytokines like TNF-a, which we confirmed in
our study as well. TNF-a is one of the first cytokines whose
production and secretion has been linked with the occupa-
tion of alpha-adrenergic receptors (a-ARs) or b-ARs by cate-
cholamines (Severn et al. 1992). Interestingly, TNF-a levels in
our patients were dependent on the severity of IS, with the
more severe group (NIHSS >12) levels constantly increasing
from the first to third and seventh day, while the less severe
group (NIHSS 12) had a significant increase from the first to
third day, with a subsequent decrease in values on the sev-
enth day. The patients with TIA did not have significant dif-
ferences between measurements. These results indicate that
the inflammation in the more severe group hasn’t subsided,
most likely due to the higher tissue damage and activation
of the SNS.
Further systemic effects of SNS activation are focussed on
the cardiovascular system, the spleen, liver, adipose tissue
and bone marrow. The negative effects on the cardiovascular
system, primarily through the activation of a-1 and b-1 adre-
noreceptors lead to reduced cardiac blood flow and constric-
tion of the coronary arteries (Di Carli et al. 1997).
Furthermore, increased SNS activity has been described as
proarrhythmogenic, which in unison with previously men-
tioned effects, can cause myocardial infarction, sudden car-
diac death and heart failure (Florea and Cohn 2014).
The effects on the cardiovascular system and the previ-
ously mentioned peripheral immunodepression can lead to
negative outcomes if the SNS activity is significant. In our
study, the patients with an increase in VMA and HVA values
from the first and third day had negative outcomes com-
pared to patients whose values decreased. A possible reason
for that could be the higher SNS activation and the negative
effects it has on cardiovascular and the immune system. On
the other hand, parasympathetic nervous system is known to
be anti-inflammatory, as acetylcholine attenuates proinflam-
matory cytokine release (Kenney and Ganta 2014). The cho-
linergic anti-inflammatory pathway has been described both
in the CNS and in the peripheral blood through the known
effector cells, the macrophages and the microglia.
Acetylcholine activates the nAChRa7 receptors on macro-
phages and microglial cells, which attenuates the inflamma-
tory response peripherally and centrally (Hao et al. 2011,
Shytle et al. 2004). Furthermore, vagal nerve stimulation
(VNS) has been shown to attenuate cerebral ischaemic injury




























et al. 2009). VNS is used to treat epilepsy, a neurological dis-
order also followed by an increase in SNS activity (Connor
et al. 2012). VNS and the activation of the cholinergic anti-
inflammatory pathway could have therapeutic potential in
patients with stroke, especially in patients who have more
pronounced ANS disturbance, which we followed in this
study using the HVA and VMA as markers of SNS activity.
Measuring parasympathetic activity is possible in a similar
way, by simultaneously measuring acetylcholine and its
metabolite choline as markers in the urine (Kirsch et al.
2010). Combining the measurements of SNS and PNS could
provide additional useful information regarding ANS inter-
action in patients with ischaemic stroke.
Conclusion
The prognostic value of measuring VMA and HVA values
comes from the comparison of the first and third day of
treatment, as the increase of values is linked to unfavourable
outcomes, while a decrease is linked to favourable outcomes.
Therefore, measuring levels of catecholamine metabolites can
provide important or even unique insight into pathophysi-
ology and course of the disease, while also helping to decide
on possible therapeutic changes, especially if treatment that
increases parasympathicus activity is found effective.
We conclude that determining VMA and HVA values in
urine could be an effective and easily available prognostic
tool for the outcome of patients suffering from IS, since tak-
ing diagnostic material is easy and sampling frequency is
low.
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